She presented a conference untitled :Â gene therapysytrategies for neurodegenerative diseases : from genetic to complex diseases
Brainvectis received the Orphan Drug Designation (ODD)Â from the European Commission for BV-CYP01, its gene therapy drug candidate for the treatment of Huntingtonâ€™s disease.
Brainvectis will participate in the European Society of Gene and Cell Therapy, that will be held at Lausanne, Switzerland.
Nathalie Cartier will give an oral presentation on Tuesday 16th October during the CNS session entitled Â«Â Gene Therapy for Huntingtonâ€™s diseaseÂ Â».
Sandro Alves will give an oral presentation on friday 19th October during the CNS session entitled Â«Â CYP46A1 gene therapy alleviates spinocerebellar ataxia in mouse modelsÂ Â».
Sandro Alves participated in the Gene Therapy partnering day, held at the Institut des Maladies GÃ©nÃ©tiques, organized by Medicen/Imagine (Paris). Sandro Alves introduced Brainvectis in the session Â«Â Innovative Technological SolutionsÂ Â» as an example ofÂ start-up translating academic preclinical research into industrial development.
Brainvectis has closed a financing round of â‚¬ 1.1 million from private investors. The funds will allow the company to move forward its programs while preparing a next financing operation in 2018.
On november 21st,Â Head of preclinical research Dr. Sandro Alves presented Brainvectis as an example ofÂ spin-off translating academic preclinical research into industrial development.
NeurATRIS is a research infrastructure conceived to accelerate the translation of discoveries in basic research into medical innovations for the treatment of diseases of the nervous system.
Brainvectis will be incubated at IPEPS, theÂ Brain and Spine instituteâ€™s (ICM)Â startup incubator and the first innovation accelerator dedicated to brain diseases in France.